Abstract
Clinical evidence of favorable outcome in patients with spontaneous early reperfusion encouraged us to use a thrombolytic agent in hyperacute embolic stroke patients [1,2]. We have reported earlier the results of a placebo-controlled, double-blind trial of 20 million international units (MIU) of recombinant tissue plasminogen activator (rt-PA, duteplase) in hyperacute embolic stroke [3,4]. The study suggested that 20 MIU of intravenous rt-PA was safe and effective for treatment of acute embolic stroke, if it was applied within 6 h of onset in patients with arterial occlusions of the internal carotid axis and with no apparent hypodensity on computed tomographic (CT) scans.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Minematsu K, Yamaguchi T, Omae T (1992) Spectacular shrinking deficit: rapid recovery from a major hemispheric syndrome by migration of an embolus. Neurology 42: 157–162
Yamaguchi T, Hayakawa T, Kikuchi H, Abe T (1991) Thrombolytic therapy in thrombotic and embolic cerebral infarction: a cooperative study. In: Hacke W, del Zoppo GJ, Hirschberg M (eds) Thrombolytic therapy in acute ischemic stroke. Springer, Berlin Heidelberg New York, pp 168–174
Yamaguchi T, Hayakawa T, Kikuchi H, for the Japanese Thrombolysis Study Group (1993) Intravenous tissue plasminogen activator in acute thromboembolic stroke: a placebo-controlled, double-blind trial. In: del Zoppo GJ, Mori E, Hacke W (eds) Thrombolytic therapy in acute ischemic stroke, II. Springer, Berlin Heidelberg New York, pp 59–65
Yamaguchi T, Hayakawa T, Kikuchi H, for the Japanese Thrombolysis Study Group (1993) Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc Dis 3: 269–272
Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, Kitano K, Tsutsumi A, Yamadori A (1992) Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 42: 976–982
Von Kummer R, Hacke W (1992) Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke 23: 646–652
Adams RL, Meador KJ, Sethi KD, Grotta JC, Thompson DS (1987) Graded neurological scale for use in acute hemispheric stroke treatment protocols. Stroke 18: 665–669
del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin JA, Wechsler L, Busse O. Greenlee RJ, Brass L, Mohr JP, Feldmann E, Hacke W, Kase CS, Biller J, Gress D, Otis SM (1992) Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 32: 78–86
Author information
Authors and Affiliations
Consortia
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag Tokyo
About this paper
Cite this paper
Yamaguchi, T., Kikuchi, H., Hayakawa, T., for the Japanese Thrombolysis Study Group. (1995). Clinical Efficacy and Safety of Intravenous Tissue Plasminogen Activator in Acute Embolic Stroke: A Randomized, Double-Blind, Dose-Comparison Study of Duteplase. In: Yamaguchi, T., Mori, E., Minematsu, K., del Zoppo, G.J. (eds) Thrombolytic Therapy in Acute Ischemic Stroke III. Springer, Tokyo. https://doi.org/10.1007/978-4-431-68459-6_27
Download citation
DOI: https://doi.org/10.1007/978-4-431-68459-6_27
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-70139-2
Online ISBN: 978-4-431-68459-6
eBook Packages: Springer Book Archive